Response Genetics Q3 Revenues Fall 24 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Response Genetics today said that its revenues in the third quarter dropped 24 percent year over year as both pharmaceutical client and ResponseDX revenues fell.

The firm's total revenues for the third quarter came in at $4.1 million, down from $5.4 million a year ago. Pharma client revenues decreased 35 percent year over year, the Los Angeles-based molecular diagnostics shop said, adding that ResponseDX revenues were down 16 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.